how many people are on glp 1 drugs Poll: in 8 Adults Say They Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Are Difficult to Afford GLP-1 Agonists Weight Loss Drugs

Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

Wang, L., Xu, R., Kaelber, D

[PubMed] [Google Scholar] 21.Davies M

Patients with a diagnosis of active IIH were identified and recruited from a single tertiary referral hospital (University Hospitals Birmingham NHS Foundation Trust)

Taken together, these findings suggest that GLP-1RAs are poised to reshape the therapeutic landscape by integrating metabolic, cardiovascular, renal, hepatic, and potentially neurological benefits

A 2024 study led by Wang, Volkow, and colleagues examined two cohorts totaling over 682,000 individuals with either obesity or type 2 diabetes and found the risk of new alcohol use disorder diagnoses was about 50% lower among those taking semaglutide compared to other anti-obesity or diabetes medications (Wang et al., 2024a)